BENEFIT Kids | Conferences
2022 Union World Conference
The BENEFIT Kids Project, funded by Unitaid, aims to improve MDR-TB treatment for children, improving their health and reducing childhood deaths. In 2022, we presented important findings at the virtual Union World Conference on Lung Health 2022 (November 8-11) that were well-received:
- Delamanid Tablets for Children: Dispersed 50mg delamanid tablets have the same effectiveness as whole tablets. This means they can be used in children and patients who can't swallow whole tablets, improving treatment accessibility.
- Treatment Outcomes in Young Children: We conducted a global analysis of individual patient data to assess the impact of bedaquiline and delamanid on treatment outcomes in children under 3-6 years old with rifampicin-resistant tuberculosis. This helps us understand their effectiveness and safety in young children.
- Predictors of Treatment Outcomes in Children: In our efforts to enhance the treatment of paediatric rifampicin-resistant tuberculosis (RR-TB), we conducted a comprehensive global review and individual patient data meta-analysis. This extensive study examined demographic, clinical, and treatment factors that influenced outcomes in 20,395 children and adolescents (0-19 years) receiving treatment for RR-TB.
- Optimising Levofloxacin Formulations for Children: We conducted a crossover study comparing the pharmacokinetics of novel dispersible (paediatric) and standard non-dispersible (adult) levofloxacin formulations in children receiving routine preventive therapy for rifampicin-resistant tuberculosis. The study revealed differences in bioavailability and exposure between the formulations, prompting the development of new, optimised dosing strategies based on age and weight for globally available formulations.